Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.89 USD | +1.43% | -1.59% | -11.42% |
Business Summary
Number of employees: 167
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug Products
100.0
%
| 214 | 100.0 % | 398 | 100.0 % | +85.90% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 214 | 100.0 % | 398 | 100.0 % | +85.90% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Stanley Iyadurai
CTO | Chief Tech/Sci/R&D Officer | - | 18-08-19 |
Brian Elsbernd
CMP | Compliance Officer | 60 | 16-02-28 |
Steven Miller
COO | Chief Operating Officer | 62 | 07-03-31 |
Gary Ingenito
CTO | Chief Tech/Sci/R&D Officer | 68 | 15-05-31 |
Charles O'Keeffe
BRD | Director/Board Member | 84 | 04-11-30 |
Mary Coleman
IRC | Investor Relations Contact | - | 21-08-15 |
Preethi Sundaram
PRN | Corporate Officer/Principal | 47 | 21-07-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Charles O'Keeffe
BRD | Director/Board Member | 84 | 04-11-30 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Molly Harper
BRD | Director/Board Member | 48 | 21-06-28 |
Tamar Thompson
BRD | Director/Board Member | 50 | 23-05-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 118,011,092 | 110,678,237 ( 93.79 %) | 0 | 93.79 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,414,688 | 11.21% | 15,345,290 $ |
Company contact information
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle Suite 801
33134, Coral Gables
+305 420 3200
http://www.catalystpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.42% | 1.76B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- CPRX Stock
- Company Catalyst Pharmaceuticals, Inc.